Market Research Future (MRFR) has announced a new release on the Global Circulating Tumor Cell Market. The report presents a detailed analysis of the market’s likely growth trajectory and drivers over the forecast period from 2018 to 2023, based on a solid examination of the market’s growth over the past few years. According to the report, the Global Circulating Tumor Cells Market was valued at USD 9,393.1 mn in 2017 and is expected to rise to a valuation of USD 28,300 mn by the end of 2023.
Additional factors substantiating the market growth include increasing per capita healthcare expenditures, increasing population, exposures to harmful radiation, and the heredity reasons and genetic mutations (abnormal changes) that could cause cancer. Well-spread awareness among the researchers about the vital role the CTC could play in delivering the effective cancer treatment.
Further substantial investments that are getting transpired in the R&D projects are in turn, paying off well bringing up the novelties and developments in the CTC mechanisms, which as a result are fostering the market growth.
Unavailability of comprehensive treatments especially in the developing regions presages the large scope for the market to evolve further, prompting significant investments for bringing betterments.
However, the rarity of circulating tumor cells is predominant factor hampering the market growth of CTC, limiting researches based on it.
Global Circulating Tumor Cell Market – Competitive Landscape
The global CTC market appears intensely competitive with the several large and small players forming a competitive edge in the market incorporating strategic partnership, collaboration, acquisition, expansion, and technology launch. Significant investments are transpired in the field to bring innovations to the therapy and clinical trials.
Get Sample Report @ https://www.marketresearchfuture.com/sample_request/1362
Some of the eminent leaders of the market include Greiner Bio-One International GmbH, Ikonisys Inc., Thermo Fisher Scientific, STEMCELL Technologies, SRI International, Miltenyi Biotec, QIAGEN Hannover (QIAGEN), Menarini Silicon Biosystems, F. Hoffmann-La Roche Ltd, Fluxion Biosciences, Inc., NanoString Technologies, Inc, GE Healthcare, Advanced Cell Diagnostics, Inc. (Bio-Techne Corporation), ApoCell, Celltraffix Inc., and Epic Lifesciences.
Industry/ Innovation/Related News:
In May 2018, CellMax launched a new clinical trial in an effort to validate its CTC screening test for colorectal cancer in the U.S.
September 17, 2018 – Scientists at the University of California, Los Angeles (US) published in the Proceedings of the National Academy of Sciences the study of a mechanism for characterizing the function of rare tumor cells which they have developed.
These researchers have created a quick and effective mechanism to measure how these cells perform functions that drive the disease, such as producing proteins that degrade tissue. Their findings could lead to more personalized treatments for people with cancer.
September 19, 2018 – ApoCell, Inc. (US), a leader global in specialty clinical Research Company involved in the capture and analysis of CTC, unveiled the biomarker results from the BEACON Phase 3 clinical trial utilizing Apocell’s proprietary circulating tumor cell enrichment system, ApoStream®. It is one of its own kind of publication that shows changes in a therapeutic target biomarker detected in CTCs that impacts overall survival in an important subset of metastatic breast cancer (MBC) patients.
Global Circulating Tumor Cell Market – Segments
MRFR has segmented its analysis into four Key dynamics for an easy grasp;
By Applications: Clinical, Research, and Drug Development among others.
By Technologies: CTC Enrichment, CTC Detection, and Combined Enrichment and Separation of CTC (CTC analysis) among others.
By End-Users: Hospital & Clinics, Research & Academic Institutes, and Diagnostic Centers among others.
By Regions: APAC, North America, Europe, and the Rest-of-the-World.
Global Circulating Tumor Cell Market – Geographical Analysis
The North American region leads the circulating tumor cell market globally; the growth is largely supported by the U.S. with the increasing prevalence of types of cancer as consequences of the wrong lifestyle. Besides, technological advancements getting transpired in the medical science and biotechnology alongside the substantial healthcare expenditure support the market growth.
The European region stands as another lucrative market for the circulating tumor cell. The market is growing owing to the increasing number of cancer patients in the region. Furthermore, the proliferation of advanced treatment facilities alongside the availability of skilled medical professionals, and the government support for research & development drives the market in the region. Moreover, factors such as technological advancement and well-spread awareness among people towards cancer and its consequences drive the growth of the regional market.
Browse Complete 110 Pages Premium Research Report Enabled with Tables and Figures @ https://www.marketresearchfuture.com/reports/circulating-tumor-cell-market-1362
The CTC market in the Asia Pacific region is emerging as a promising market owing to the increasing number of cancer patients. Factors substantiating market growth include the increasing prevalence of cancer, spreading awareness among people about cancer, and the availability of new treatment methods. Proliferating markets in China and India majorly contribute to the market growth in the region.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar
Pune – 411028
+1 646 845 9312